Skip to main content
EyePoint Pharmaceuticals, Inc. logo

EyePoint Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · EYPT ISIN · US74440J1016 LEI · 549300QE1RU34T50MR69 US Manufacturing
Open in API
Filings indexed 1,019 across all filing types
Latest filing 2013-02-08 Interim / Quarterly Rep…
Country US United States of America
Listing US EYPT

About EyePoint Pharmaceuticals, Inc.

https://eyepointpharma.com/

EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for serious retinal diseases. The company leverages its proprietary Durasert E™ technology, a bio-erodible platform for sustained intraocular drug delivery, to create durable therapies. Its lead investigational product, DURAVYU™ (EYP-1901), combines the tyrosine kinase inhibitor vorolanib with the Durasert E™ system for the potential treatment of VEGF-mediated retinal diseases. The company's goal is to improve patient outcomes and reduce treatment burden by providing long-lasting treatments for chronic eye conditions.

Recent filings

Filing Released Lang Actions
FORM 10-Q
Interim / Quarterly Report Q2 2013
2013-02-08 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions that the company issued a press release announcing its second quarter fiscal year 2013 results. The document includes a press release as an exhibit but does not contain detailed financial statements or comprehensive financial analysis itself. The length is 2666 characters, which is relatively short and consistent with a current report or announcement rather than a full financial report. The document is not a full quarterly or annual report but a regulatory filing announcing financial results. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and includes Form 8-K filings.
2013-02-06 English
Regulatory Filings 2013
Regulatory Filings
2013-01-24 English
Regulatory Filings 2013
Regulatory Filings Classification · 95% confidence The document is a letter from pSivida Corp. to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-3. It is correspondence related to a regulatory filing process, specifically about the registration statement becoming effective. The document does not contain financial data, report content, or detailed disclosures itself, but is a procedural communication. It is short (1953 characters) and serves as a request rather than a report or announcement of results. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and correspondence that do not fit other categories.
2013-01-23 English
AMENDMENT NO.1 TO FORM S-3
Capital/Financing Update Classification · 100% confidence The document is titled 'Amendment No. 1 to Form S-3' and is a registration statement filed with the SEC under the Securities Act of 1933. It includes detailed information about the company's securities offering, including common stock, warrants, preferred stock, and units, with a maximum gross proceeds amount. The document contains a prospectus with risk factors, company business description, and legal disclaimers. Form S-3 is a registration statement used for securities offerings and is related to capital raising activities. This is not a financial report, earnings release, or management discussion, but rather a capital/financing update filing. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full registration statement amendment, not just an announcement or notice, supporting a high confidence level.
2013-01-17 English
Regulatory Filings 2013
Regulatory Filings
2013-01-08 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.